dm+d

Unassigned

New Medicines

Gastric cancer or or gastroesophageal junction (GEJ) adenocarcinoma - first-line with chemotherapy

Information

New molecular entity
Astellas
Astellas

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Antibody to CLDN18.2 protein that is abundant in gastric tumors
Gastric cancer is the second most common cancer world-wide. The largest numbers are in older patients and incidence rises steeply after age 55. UK 5-year survival rate is 5-12% in those over 70 [2].
Gastric cancer or or gastroesophageal junction (GEJ) adenocarcinoma - first-line with chemotherapy
Bladder instillation